Reata Pharmaceuticals, Inc. Announces Interim Data From Extension Phase 2 LARIAT Study in Pulmonary Arterial Hypertension (Reata Pharmaceuticals Inc)

(Source: Reata Pharmaceuticals Inc) IRVING, Texas, June 23, 2016 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) ('Reata'), a clinical-stage biopharmaceutical company, today announced interim data from the extension Phase 2 LARIAT trial of bardoxolone methyl for the treatment of pulmonary arterial hypertension ('PAH'). The increase in six minute walk distance ('6MWD') through 16 weeks of treatment that was previously reported was sustained through 32 weeks of treatment and was not significantly different from that at week 16 in the same set of patients. Bardoxolone methyl-treated patients with connective tissue disease ('CTD')-associated PAH had similar sustained increases in...